Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DB26FDQDU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,332
Award facts
- Contract value 100% obligated
- $8,331.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $8,331.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Nexplanon 68 mg implants. The delivery order, issued on October 23, 2025, with an ultimate completion date of November 14, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is fulfilling this requirement under its single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supporting Department of Defense pharmaceutical supply needs.
DMS Pharmaceutical Group maintains a comprehensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The contractor's established performance across numerous delivery orders issued by DLA's Medical Supply Chain division demonstrates its capability to support the diverse pharmaceutical requirements of military healthcare facilities. The company's PPV-G GEN V prime vendor contract, valued at $499,999,999 with a completion date of December 31, 2036, positions it as a critical supplier within the federal military medical system's pharmaceutical supply chain, with authority to fulfill recurring medical supply needs across Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FDQDU?
SPE2DB26FDQDU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FDQDU worth?
The government has obligated $8,332 on SPE2DB26FDQDU.
Is contract SPE2DB26FDQDU an order under another contract?
Yes. SPE2DB26FDQDU is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB26FDQDU competed?
The extent of competition for SPE2DB26FDQDU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award